Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study by Heuvelmans, Marjolein A et al.
Contents lists available at ScienceDirect
Lung Cancer
journal homepage: www.elsevier.com/locate/lungcan
Relationship between nodule count and lung cancer probability in baseline
CT lung cancer screening: The NELSON study
Marjolein A Heuvelmansa,b,⁎, Joan E Waltera, Robin B Petersc, Geertruida H de Bockd,
Uraujh Yousaf-Khane, Carlijn M van der Aalste, Harry J M Groenf, Kristiaan Nackaertsg,
Peter MA van Ooijena, Harry J de Koninge, Matthijs Oudkerka, Rozemarijn Vliegentharta
a University of Groningen, University Medical Center Groningen, Center for Medical Imaging − North East Netherlands, Hanzeplein 1, 9713 GZ, Groningen, The
Netherlands
b Department of Pulmonology, Medisch Spectrum Twente, Enschede, The Netherlands
c Department of Radiology, AZ Sint-Maria Halle, Ziekenhuislaan 100, 1500 Halle, Belgium
d Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
e Department of Public Health, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
f University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands
g Department of Pulmonary Medicine, KU Leuven − University Hospital Leuven, Herestraat 49, 3000, Leuven, Belgium
A R T I C L E I N F O
Keywords:
Lung neoplasms
Pulmonary nodule
Computed tomography
Mass screening
A B S T R A C T
Objectives: To explore the relationship between nodule count and lung cancer probability in baseline low-dose
CT lung cancer screening.
Materials and Methods: Included were participants from the NELSON trial with at least one baseline nodule
(3392 participants [45% of screen-group], 7258 nodules). We determined nodule count per participant.
Malignancy was conﬁrmed by histology. Nodules not diagnosed as screen-detected or interval cancer until the
end of the fourth screening round were regarded as benign. We compared lung cancer probability per nodule
count category.
Results: 1746 (51.5%) participants had one nodule, 800 (23.6%) had two nodules, 354 (10.4%) had three no-
dules, 191 (5.6%) had four nodules, and 301 (8.9%) had > 4 nodules. Lung cancer in a baseline nodule was
diagnosed in 134 participants (139 cancers; 4.0%). Median nodule count in participants with only benign no-
dules was 1 (Inter-quartile range [IQR]: 1–2), and 2 (IQR 1–3) in participants with lung cancer (p = NS). At
baseline, malignancy was detected mostly in the largest nodule (64/66 cancers). Lung cancer probability was
62/1746 (3.6%) in case a participant had one nodule, 33/800 (4.1%) for two nodules, 17/354 (4.8%) for three
nodules, 12/191 (6.3%) for four nodules and 10/301 (3.3%) for > 4 nodules (p = NS).
Conclusion: In baseline lung cancer CT screening, half of participants with lung nodules have more than one
nodule. Lung cancer probability does not signiﬁcantly change with the number of nodules. Baseline nodule count
will not help to diﬀerentiate between benign and malignant nodules. Each nodule found in lung cancer screening
should be assessed separately independent of the presence of other nodules.
1. Introduction
In 2011, the National Lung Screening Trial (NLST) reported a
15–20% reduction in lung cancer mortality among individuals screened
by annual low-dose CT, if compared to participants screened by annual
chest X-ray [1]. Following the publication of this positive result,
adapted guidelines were published, all recommending lung cancer
screening in a high-risk population [2–5]. A remaining problem in lung
cancer screening, however, is the high rate of false-positive screen re-
sults.
In CT lung cancer screening trials, about half of screened partici-
pants have pulmonary nodules, the overwhelming majority being be-
nign [1,6,7]. A key issue in lung cancer screening is to diﬀerentiate
benign and malignant nodules at an early stage. Several radiological
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features, such as size, growth rate, morphology, and location are as-
sociated with an increased lung cancer probability and may help radi-
ologists in adequately identifying a high-risk baseline nodule [8,9].
A commonly overlooked aspect is the number of nodules per
screenee (nodule count) at the time of nodule detection. Generally,
nodule management in lung cancer screening is based on the largest or
most suspicious nodule, but often more than one nodule is present.
While only limited data concerning the impact of nodule count on lung
cancer probability is available, one study indicated a negative linear
relationship between nodule count and lung cancer probability and
incorporated it in a risk calculator for nodules detected at baseline
screening [10].
However, in a preliminary, limited analysis on multinodularity and
lung cancer probability for nodules detected in the ﬁrst and second
screening round of the Dutch-Belgian Randomized Lung Cancer
Screening Trial (acronym NELSON), the relationship between nodule
count and lung cancer probability in participants was found to be
ambiguous, with varying lung cancer probabilities as nodule count in-
creased [7]. The purpose of this study was to explore in-depth the re-
lationship between nodule count and lung cancer probability in the
baseline round of the NELSON trial.
2. Materials and methods
2.1. NELSON trial and study participants
The NELSON trial was designed to investigate whether low-dose
spiral CT screening will decrease 10-year lung cancer mortality by at
least 25% in high-risk (ex-) smokers. The Dutch Minister of Health and
the ethics board of each participating center approved the NELSON
trial. All participants gave written informed consent. The design of the
NELSON trial, including participant selection and lung nodule man-
agement has been published [11,12]. In brief, 15,792 current and
former smokers [13], aged 50–75 years, who smoked > 15 cigarettes
daily for over 25 years or > 10 cigarettes daily for over 30 years were
included. Participants were randomized 1:1 to usual care without
screening or screening. Between April 2004 and December 2006, 7557
participants underwent baseline screening. Baseline screening was
performed in year 1, and incident screening rounds took place in year 2
(second round), year 4 (third round), and year 6.5 (fourth round). For
this retrospective analysis, we included all participants with non-cal-
ciﬁed nodules detected at baseline. We included all nonsolid, part-solid
and solid nodules with volume≥ 15 mm3 and/or sub-solid diame-
ter≥ 4 mm (study detection limits).
2.2. Lung cancer screening CT scan protocol, reading and data set
Participants were invited to one of four screening sites each using a
16-multidetector CT scanner (three Sensation-16 systems, Siemens
Medical Solutions, Forchheim, Germany and one Brilliance 16P system,
Philips Medical Systems, Cleveland, OH, USA). A non-contrast low-dose
CT scan of the entire chest was obtained in a cranio-caudal direction in
one breath-hold (about 12 s in spiral mode with 16 × 0.75 mm colli-
mation and pitch 1.3). Typical technical parameters for the low-dose
setting depended on body weight (< 50 kg, 50–80 kg and > 80 kg):
80–90 kVp, 120 kVp and 140 kVp respectively [11]. Image data sets
with isotropic voxels were available, allowing analyses with software
for semi-automated volume measurements (Syngo LungCARE, Siemens
Healthcare, Erlangen, Germany). All images were read by two in-
dependent radiologists with experience in chest CT reading ranging
between 1 and 20 years, and in case of discrepancy a third, expert
reader made the ﬁnal decision [11,14]. Radiologists could overrule a
protocol-based screening result (done for 6% of participants at the
baseline screening round) and manually adjust the volume measure-
ment in case of inappropriate segmentation [14]. Nodule management
was based on size, density and growth rate of the largest nodule. The
nodule size criteria were published before [11]. In short, NODCAT 2
comprised solid nodules with volume 15–50 mm3 and subsolid nodules
with diameter 4–8 mm, and led to a negative screen result (invitation
for regular next screening round). NODCAT 3 were solid nodules with
volume 50–500 mm3 and subsolid nodules≥ 8 mm. NODCAT 4 no-
dules were deﬁned as potentially malignant (solid, > 500 mm3, posi-
tive screen result), and required immediate referral to the pulmonolo-
gist for work-up. NODCAT 3 nodules were assigned an indeterminate
test result, requiring a repeat scan after 3–4 months to assess nodule
growth. Growth was deﬁned as change in volume of > 25% and vo-
lume doubling-time was calculated as described previously [11,15].
Screenees having a nodule with volume doubling time<400 days (fast
growing, positive screen result) were referred to a pulmonologist for
work-up.
2.3. Nodule characteristics
Both readers reported information regarding nodule volume, loca-
tion, distance to costal pleura and margin. Nodule location was deﬁned
as upper lobe (middle, left or right upper lobe) or lower lobe (left or
right lower lobe). In case of distance to costal pleura less than one-third
of the total distance of hilum-costal pleura, nodules were considered to
be peripheral, and with more than one-third of the total distance, no-
dules were considered to be non-peripheral. Nodule margin was clas-
siﬁed as smooth, lobulated, spiculated or irregular [16].
2.4. Nodule count
Nodule count was deﬁned as the number of non-calciﬁed lung no-
dules present in the baseline screening round. We compared nodule
count at baseline for participants with only benign nodules and parti-
cipants with lung cancer. Five categories based on nodule count were
deﬁned: 1 nodule, 2 nodules, 3 nodules, 4 nodules and > 4 nodules.
Histology was the reference for diagnosis. In case a nodule was not
diagnosed as screen-detected lung cancer or interval cancer until the
end of the fourth screening round, the nodule was regarded as benign.
2.5. Statistical analysis
Descriptive statistics were reported as numbers and percentages. We
tested data distribution with normality plots. Normally distributed
variables were described by mean and 95% conﬁdence interval (95%-
CI), while non-normally distributed variables were described by median
and inter-quartile range (IQR). We assessed the relationship of parti-
cipant age and smoked pack-years with nodule count by using
Spearman’s rank correlation coeﬃcient. We derived lung cancer prob-
ability per screenee and per nodule for categories based on number of
baseline nodules, by dividing the number of lung cancer cases per ca-
tegory by number of screenees and number of nodules, respectively. We
tested the relationship between the presence of lung cancer and the
number of baseline nodules by using chi-square. We used SPSS Statistics
version 22 (IBM, Armonk, NY) for all analyses, and considered a p-value
of < 0.05 as statistically signiﬁcant.
3. Results
3.1. Characteristics of study population
In this study, we included 3392 participants with 7258 non-calciﬁed
baseline nodules (45% of all screen-group participants). Median parti-
cipant age was 58 years (IQR 55–63 years); 84.4% (2863/3392) were
male (Table 1). In total, 1746 participants (51.5%) had one nodule, 800
(23.6%) had two nodules, 354 (10.4%) had three nodules, 191 (5.6%)
had four nodules, and 301 (8.9%) had ﬁve or more nodules. Fig. 1
shows the distribution of nodule count per participant.
The percentage of screenees with actionable nodules (NODCAT 3 or
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4; short-term follow-up or referral) increased linearly with the number
of baseline nodules, from 36.4% to 90.0% (Table 1). Spearman’s cor-
relation coeﬃcient showed slightly more nodules by increasing age
(correlation coeﬃcient 0.044; p = 0.01). No diﬀerence was found in
number of nodules by smoked pack-years (correlation coeﬃcient 0.026;
p = 0.13).
3.2. Description of cancers in study population
During four screening rounds, 139 baseline nodules in 134 partici-
pants were proven to be lung cancer. Simultaneous double tumours
were found in ﬁve participants. Of the 139 cancers, 70 were diagnosed
to be malignant immediately after the baseline round (66 screenees). At
baseline, lung cancer was histologically conﬁrmed in the largest nodule
in 64/66 (97.0%) screenees (double tumours counted once), and in the
second largest detected nodule in 2/66 (3.0%) cases. In later rounds,
49/56 (87.5%) screen-detected lung cancers and 10/12 (83.3%) in-
terval cancers were found in baseline nodules that were the largest at
the baseline CT. On population basis, median nodule count was 1 (IQR
1–2) in participants with only benign nodules, and 2 (IQR 1–3) in
participants with lung cancer. Range of nodule count was equal for
participants with only benign nodules and participants with lung cancer
(1–18 nodules).
3.3. Nodule characteristics
Baseline nodules most often were located in the lower lobes, in the
periphery of the lung, and had a smooth shape. Compared to benign
baseline nodules, malignant nodules were larger and more often sub-
solid, had more often a non-smooth margin, and were more often
located in the upper lobes of the lung. Nodule characteristics per nodule
count are shown in Table 2.
3.4. Lung cancer probability: participant-based analysis
In 62 of 1746 participants with one baseline nodule (3.6%; 95% CI,
2.8-4.6%), the solitary nodule was lung cancer. Of 800 participants
with two lung nodules, 33 (4.1%; 95% CI, 2.9-5.8%) were diagnosed
with lung cancer in one of these nodules. In 17 of 354 participants with
three nodules (4.8%; 95% CI, 2.9-7.7%), 12 of 191 participants with
four nodules (6.3%; 95% CI, 3.4-11.0%), and ten of 301 participants
with at least ﬁve nodules (3.3%; 95% CI, 1.7-6.2%), lung cancer was
diagnosed (Table 3). Lung cancer probability did not diﬀer signiﬁcantly
for the diﬀerent nodule count categories (p = 0.34).
Of the 12 participants with a baseline nodule diagnosed as interval
cancer, three participants had a single baseline nodule, ﬁve had two
nodules at baseline, two had three baseline nodules, one had four and
one had > 4 nodules at baseline.
3.5. Lung cancer probability: nodule-based analysis
Lung cancer probability per nodule was 3.6% in case of one nodule,
2.1% in case of two nodules, 1.8% in case of three nodules, 1.7% in case
of four nodules and 0.7% in case of screenees with more than four
nodules.
Table 4 shows an increasing lung cancer risk in increasing nodule
categories (overall; NODCAT 2 0.3%, NODCAT 3 2.5% and NODCAT 4
30.1%). There was no diﬀerence in lung cancer probability for a
NODCAT 2 nodule found in screenees with only one nodule or
screenees with a higher nodule count. For actionable nodules
Table 1
Characteristics of participants with at least one pulmonary nodule at baseline screening round.
All participants 1 Nodule 2 Nodules 3 Nodules 4 Nodules > 4 Nodules
N = 3,392 N = 1,746 N = 800 N= 354 N= 191 N = 301
Age Median 58 58 59 59 59 59
IQR 55–63 54–63 55–63 55–63 55–64 55–63
Pack Years Median 38.0 37.9 38.7 37.9 38.7 37.9
IQR 29.7–49.5 29.7–49.5 29.7–49.5 29.7–49.5 31.2–53.2 29.7–49.5
Gender Male N (%) 2,863 (84.4) 1,455 (83.3) 674 (84.3) 298 (84.2) 169 (88.5) 267 (88.7)
NODCAT_maxa 2, N (%) 1,616 (47.6) 1,109 (63.5) 333 (41.6) 106 (29.9) 38 (19.9) 30 (10)
3, N (%) 1,588 (46.8) 570 (32.6) 416 (52.0) 219 (61.9) 134 (70.2) 249 (82.7)
4, N (%) 188 (5.5) 67 (3.8) 51 (6.4) 29 (8.2) 19 (9.9) 22 (7.3)
a Largest nodule at baseline screening. A NODCAT 2 nodule is solid nodules with volume 15–50 mm3 or sub-solid with diameter 4–8 mm, a NODCAT 3 nodule is solid with volume
50–500 mm3, or sub-solid ≥8 mm, and a NODCAT 4 nodule is solid> 500 mm3.
Fig. 1. Distribution of nodule count in 3389 participants at baseline
lung cancer screening.
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(> 50 mm3; NODCAT 3 or 4), the risk of malignancy in a particular
nodule decreased in case a nodule was found in screenees with four or
more nodules per screenee, compared to actionable nodules found in
screenees with only one nodule (p < 0.001 for NODCAT 3 and
p < 0.05 for NODCAT 4 nodules).
4. Discussion
With the use of multi-detector low dose CT scanners (very) small
lung nodules can be detected, the minority being malignant. Whether
the number of lung nodules (nodule count) plays a role in the de-
termination of lung cancer probability still remains largely unknown.
This study shows that at baseline CT lung cancer screening, nearly half
of screening participants with lung nodules have more than one lung
nodule (1746/3392 [51.5%]), representing about one-fourth of all
screenees. We found no statistically signiﬁcant relationship between
nodule count and lung cancer probability in participants with baseline
nodules. We observed a non-signiﬁcant trend whereby lung cancer
probability increased as a function of nodule count, with a peak in lung
cancer probability in subjects with four baseline nodules (6.3%).
However, this non-signiﬁcant increasing trend did not continue. The
implications of these ﬁndings partly diﬀer from previous observations
by McWilliams et al., where nodule count was incorporated in a model
for the prediction of malignancy in pulmonary nodules [10]. In their
risk calculator, they found a linear reduction of a baseline nodule’s lung
cancer probability with an increased number of pulmonary nodules per
screenee.
In our subgroup of the NELSON study containing all participants
with non-calciﬁed baseline nodules, we found lung cancer in a baseline
nodule in 134/3392 (4.0%) participants, up to six years after baseline
(information regarding new nodules was published elsewhere [17]). In
the PanCan study, the overall rate of malignancy was 5.5%. In com-
parison to the ﬁndings of McWilliams et al. [10], we found a much
lower mean nodule count per screened participant. The subjects with
benign nodules in the PanCan study had a mean of 6.2 nodules, com-
pared to 2.1 nodules (median 1 nodule) in our study. In the PanCan
Table 2
Nodule characteristics detected at baseline screening round.
Number of Nodules 1 Nodule 2 Nodules 3 Nodules 4 Nodules > 4 Nodules Benign Malignant P-value
Volume (mm3)a Median 36.9 38.3 38.3 38.6 38.9 37.7 328.6 < 0.001
IQR 23.8–69.0 24.1–70.3 25.1–70.1 24.9–71.6 24.6–67.5 24.2–67.3 112.7–1130.5
NodCat 2 959 (64.0) 972 (62.0) 707 (63.5) 476 (62.3) 1444 (62.4) 4545 (63.8) 13 (9.4) < 0.001
3 484 (32.3) 537 (34.2) 374 (33.6) 263 (34.4) 834 (36.0) 2430 (34.1) 64 (46.0)
4 55 (3.7) 60 (3.8) 32 (2.9) 25 (3.3) 36 (1.6) 144 (2.0) 62 (44.6)
Nodule Typeb Solid 1439 (96.8) 1504 (96.5) 1074 (96.7) 744 (97.4) 2277 (98.6) 6915 (97.5) 123 (88.5) < 0.001
Part-solid 15 (1.0) 27 (1.7) 18 (1.6) 8 (1.0) 11 (0.5) 72 (1.0) 7 (5.0)
Nonsolid 33 (2.2) 28 (1.8) 19 (1.7) 11 (1.4) 21 (0.9) 103 (1.5) 9 (6.5)
Locationc,d Upper Lobe 569 (38.6) 620 (40.0) 381 (34.9) 276 (34.9) 760 (34.2) 2517 (36.2) 89 (64.0) < 0.001
Lower lobe 906 (61.4) 929 (60.0) 712 (65.1) 472 (63.1) 1465 (65.8) 4434 (63.8) 50 (36.0)
Peripheral 1204 (81.6) 1252 (80.7) 923 (83.2) 623 (81.9) 1983 (86.1) 5872 (83.1) 113 (81.9) 0.73
Non-peripheral 271 (18.4) 300 (19.3) 186 (16.8) 138 (18.1) 321 (13.9) 1191 (16.9) 25 (18.1)
Shapee Non-smooth 89 (6.9) 108 (7.8) 67 (6.9) 30 (4.8) 65 (3.1) 299 (4.9) 60 (45.5) < 0.001
Smooth 1206 (93.1) 1276 (92.2) 903 (93.1) 594 (95.2) 1920 (96.7) 5827 (95.1) 72 (54.5)
Unless otherwise indicated, data are numbers of nodules, with percentages in parenthesis. Abbrevations: IQR– Interquartile range.
a In 193/7258 (2.7%) no volume measurement was possible, for instance in sub-solid nodules.
b In 29/7258 (0.4%) nodule type was not speciﬁed, mostly due to very small nodule size ( < 50mm3).
c,d In 225/7258 (3.1%) location was not speciﬁed (168/7258 (2.3%) peripheral versus non peripheral and 57/7258 (0.8%) upper versus lower lobe).
e In 1000/7258 (13.8%) nodule shape was not speciﬁed, mostly due to very small nodule size (< 50mm3).
Table 3
Lung cancer probability with 95% conﬁdence intervals on participant basis: cancer detection at baseline versus at later screening rounds.
Nodule Count Participants Total
Cancer
Lung cancer
probability
95% CI Baseline
Cancer
Lung cancer
probability
Baseline
95% CI
Baseline
Cancer in
later round*
Lung cancer
probability
Incidence round
95% CI
Incidence
round
1 Nodule 1746 62 3.6% 2.8–4.6% 30 1.7% 1.2–2.5% 32 1.8% 1.3–2.6%
2 Nodules 800 33 4.1% 2.9–5.8% 17 2.1% 1.3–3.5% 16 2.0% 1.2–3.3%
3 Nodules 354 17 4.8% 2.9–7.7% 6 1.7% 0.7–3.8% 11 3.1% 1.6–5.7%
4 Nodules 191 12 6.3% 3.4–11.0% 7 4.2% 2.0–8.4% 5 2.6% 1.0–6.3%
>4 Nodules 301 10 3.3% 1.7–6.2% 6 2.0% 0.8–4.5% 4 1.3% 0.4–3.6%
Total 3392 134 4.1% 3.4–4.8% 66 2.0% 1.5–2.5% 68 2.0% 1.6–2.6%
Note − Data are numbers of participants, with percentages in parenthesis.
Abbreviations: 95% CI − 95% conﬁdence interval.
* lung cancer diagnosed in a nodule already present at baseline.
Table 4
Lung cancer probability by nodule count for NODCAT* 2–4 nodules.
Baseline
NODCAT
NODCAT 2
Nodules
NODCAT 3
Nodules
NODCAT 4 Nodules
Cancer Yes No Yes No Yes No
Overall cancer 13 (0.3) 4545
(99.7)
64 (2.6) 2431
(97.4)
62 (30.1) 144 (69.9)
Nodule count
1
6 (0.5) 1102
(99.5)
29 (5,1) 543
(94.9)
27 (40.9) 39 (59.1)
Nodule count
2
4 (0.4) 988
(99.6)
16 (2.9) 536
(97.1)
15 (26.8) 41 (73.2)
Nodule count
3
3 (0.4) 682
(99.6)
9 (2.6) 334
(97.4)
7 (20.6) 27 (79.4)
Nodule count
4
0 (0) 471
(100)
7 (2.6) 265
(97.4)
6 (28.6) 15 (71.4)
Nodule
count>4
0 (0) 1302
(100)
3 (0.4) 753
(99.6)
7 (24.1) 22 (75.9)
Note − Data are numbers of nodules, with percentages in parenthesis.
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study, subjects with lung cancer had a mean of 4.8 nodules, in contrast
to our ﬁndings of 2.3 nodules on average (median 2 nodules). Diﬀer-
ences may be explained by diﬀerences in inclusion criteria for
screenees. The NELSON study recruited participants aged 50–75 years
without a history of lung cancer, who smoked > 15 pack-years. The
PanCan study used a diﬀerent approach for recruiting participants,
namely via a risk-prediction model [18]. Participants with an estimated
risk of developing lung cancer in the next 3 years of≥ 2% were in-
cluded. Geographical diﬀerences in pulmonary nodule nature (i.e.
prevalence of fungus infestations [19]) may have inﬂuenced the
number of nodules in these studies on two diﬀerent continents as well.
In 64/66 (97.0%) of participants with lung cancer detected at
baseline, malignancy was detected in the nodule with the largest vo-
lume. This contrasts with the results by McWilliams et al. [10], who
showed that in one-ﬁfth of the participants, the largest nodule was not
the one that turned out to be malignant at baseline or follow-up. This
discrepancy might be explained by the use of semi-automated, volu-
metric measurement in our study, while manual, two-dimensional
diameter measurements were performed in the PanCan study. Pre-
viously, it has been shown that nodule measurements are more accurate
with volumetric techniques compared to diameter techniques [20–22].
Possibly, diameter measurements cannot identify the largest nodule as
good as volumetry.
The American College of Radiology’s Lung Imaging Reporting and
Data System (Lung-RADS) proposed to classify screening CTs by the
nodule with highest malignant risk (usually the largest nodule) [23].
Our results conﬁrm this policy. Each nodule found in lung cancer
screening subjects should be assessed separately whereby the largest
nodule has the highest probability to be malignant.
While reporting and measuring all lung nodules might be time
consuming, it is important to lung cancer screening for two reasons.
First, new nodules are regularly found after baseline screening and were
shown to carry a higher lung cancer probability than do baseline no-
dules even at smaller size [24]. To ensure the appropriate detection of
new nodules, previously present nodules need to be well documented.
Secondly, after initial detection a nodule’s risk-stratiﬁcation relies on
growth assessment which is based on the size diﬀerence between two
scans and therefore the previous measurements [7,25].
We found that the more nodules per screenee, the greater the like-
lihood that the largest nodule was classiﬁed as indeterminate (NODCAT
3, see Table 1). Indeterminate pulmonary nodules led to an extra
follow-up CT examination after 3 months. Therefore, the more nodules
per screenee, the more follow-up scans were made to assess growth.
Higher age and number of smoked pack-years are associated with an
increased risk of developing lung cancer [10]. In our analysis, higher
age at baseline was correlated with a slightly increased risk of having
more pulmonary nodules. In contrast, no relationship was found be-
tween nodule count at baseline and number of smoked pack-years.
We included all non-calciﬁed nodules, and did not diﬀerentiate
between solid, part- solid and pure nonsolid nodules. More detailed
research on the inﬂuence of multiple nodules from diﬀerent subtypes
(solid, sub-solid) on lung cancer probability is recommended.
Furthermore, external validation of the nodule count and lung cancer
probability in high-risk screening participants needs to be performed to
conﬁrm our ﬁndings.
4.1. Conclusion
At baseline CT lung cancer screening, nearly half of screened par-
ticipants with lung nodules have more than one lung nodule, re-
presenting a quarter of all screenees. Lung cancer probability did not
signiﬁcantly change with number of nodules, therefore baseline nodule
count proved to be not useful for prediction of malignancy. Each nodule
found in lung cancer screening subjects should be assessed separately
independent of the presence of other nodules.
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